The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities
Cancers · 19.03.2026 · 18 (6) · 998
DOI: 10.3390/cancers18060998 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.03.2026. Verfasst von Jing Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, CSHL Cancer Center.
Abstract (Originalsprache)
Prostate cancer (PCa) is one of the most common malignancies in men, and growing evidence implicates the gut microbiome as a significant, modifiable contributor to disease evolution and management. Dysbiosis influences PCa biology through effects on inflammation, immune regulation, metabolism, and hormone signaling. Microbial imbalance can promote systemic inflammation and increase intestinal permeability, activating immune signaling pathways such as NF-κB–IL-6–STAT3. In parallel, microbiome-driven metabolic effects, including IGF-1 signaling and microbial androgen synthesis or recycling, may contribute to resistance to androgen deprivation therapy (ADT). Microbial metabolites, notably short-chain fatty acids (SCFAs) and trimethylamine N-oxide (TMAO), exert context-dependent effects on tumor growth, treatment resistance, and progression. Conversely, beneficial microbes have been associated with improved treatment sensitivity and immune regulation. Together, these insights support the gut microbiome as a potential biomarker and emerging therapeutic target in PCa. Modulation strategies, including diet, probiotics, antibiotics, and fecal microbiota transplantation (FMT), are being explored to improve treatment response and address resistance. As mechanistic evidence continues to grow, ongoing monitoring of the gut microbiome may help inform risk stratification and treatment optimization in prostate cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Northwell Cancer Institute, Northwell Health, New York, NY 11042, USA.
- Feinstein Institutes for Medical Research, Northwell Health, New York, NY 11030, USA.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
ORCID-Profile: Xin-Hua Zhu, Lloyd C Trotman
Förderung
- NCI NIH HHS
- National Cancer Institute
- CSHL Cancer Center
Zitieren
APA
Huang, J., Zhu, X. H., Trotman, L. C., & Tsao, C. K. (2026). The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities. Cancers, 18(6), 998. https://doi.org/10.3390/cancers18060998
Vancouver
Huang J, Zhu XH, Trotman LC, Tsao CK. The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities. Cancers. 2026;18(6):998. doi:10.3390/cancers18060998
BibTeX
@article{Huang2026,
author = {Huang, Jing and Zhu, Xin-Hua and Trotman, Lloyd C and Tsao, Che-Kai},
title = {The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities},
journal = {Cancers},
year = {2026},
volume = {18},
number = {6},
pages = {998},
doi = {10.3390/cancers18060998}
}
EUVIMED